TIPS-17 A FIRST-IN-HUMAN FEASIBILITY STUDY TO EVALUATE THE SAFETY OF SELECTIVE INTRA-ARTERIAL YTTRIUM-90 MICROSPHERE TREATMENT IN PATIENTS WITH RECURRENT GLIOBLASTOMA (THE FRONTIER TRIAL)

BACKGROUND: Glioblastoma (GBM) is the most aggressive primary brain tumor that virtually always recurs with no established standard therapy at recurrence. Median survival after recurrence is 7-12 months. Selective internal radiation therapy (SIRT) with Yttrium-90 (Y90) glass microspheres (TheraSpher...

Descripción completa

Detalles Bibliográficos
Autores principales: Mouli, Samdeep, Goyal, Piyush, Tate, Matthew, Dixit, Karan, Primdahl, Ditte, Boockvar, John, Quinones-Hinojosa,, Alfredo, Weiss, Cliffword, Butowski, Nicholas, Dreher, Matthew, Stupp, Roger, Salem, Riad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Final Category: Trials in Progress
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10402349/
http://dx.doi.org/10.1093/noajnl/vdad070.147

Ejemplares similares

Ejemplares similares